Roche, Mer­ck and Pfiz­er lead US phar­ma cor­po­rate rep­u­ta­tion rank­ing by pa­tient groups

While pa­tient groups in the US still view the phar­ma in­dus­try pos­i­tive­ly over­all, its rep­u­ta­tion is lev­el­ing out as af­ford­abil­i­ty con­cerns re­take cen­ter stage.

Al­most two-thirds (65%) of the groups ranked phar­ma cor­po­rate rep­u­ta­tions as “ex­cel­lent” or “good” in the lat­est sur­vey of pa­tient groups in the US by in­de­pen­dent re­searcher Pa­tientView. That’s down two per­cent­age points from the pre­vi­ous year but still much high­er than the pre-pan­dem­ic years of 2018 and 2019 when ap­proval hov­ered in the mid-40 per­cent­ages.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER